Discovery of HBW-3-10: A potent, orally active, reversible Bruton's tyrosine kinase (BTK) inhibitor with antitumor activity in mice.
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 20, 2021
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal